Back

Mavacamten improves functional status in obstructive hypertrophic cardiomyopathy without increasing serious adverse events: a systematic review and meta-analysis

30 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: disease burden, risk stratification, and clinical outcomes Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ivan Rafael Figueroa Baez

San Juan City Hospital, San Juan (Puerto Rico)

6 More presentations in this session

Presentation thumbnail
Longitudinal burden of disease in hypertrophic cardiomyopathy: one-year follow-up of the AFFECT-HCM study
Miss R. Mangal (Rotterdam, NL)
Abstract
Presentation thumbnail
Real-world clinical burden of obstructive hypertrophic cardiomyopathy: a nationwide study in france
Professor A. Hagege (Paris, FR)
Abstract
Presentation thumbnail
Simplified versus complete selvester QRS scoring system for scar assessment in hypertrophic cardiomyopathy patients
Doctor N. Charoenpoonsiri (Bangkok, TH)
Abstract
Presentation thumbnail
Continuous ambulatory ECG monitoring of up to 14 days increases detection of high-risk ventricular tachyarrhythmias compared with the first 48 hours in hypertrophic cardiomyopathy
Doctor M. Maron (Burlington, US)
Abstract
Presentation thumbnail
HCM in the modern era: low mortality and predominantly predictable sudden cardiac death under systematic risk stratification
Doctor E. Karvouni (Athens, GR)
Abstract

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: disease burden, risk stratification, and clinical outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Mavacamten improves symptoms of shortness of breath in patients with obstructive hypertrophic cardiomyopathy (HCM): analysis of the HCM Symptom Questionnaire in the phase 3 EXPLORER trial
30 June 2021
thumbnail
Congress Presentation
Efficacy and safety of mavacamten therapy in hypertrophic cardiomyopathy: An up-to-date systematic review and meta-analysis
11 May 2024
thumbnail
Congress Presentation
The evolution of the obstructive HCM therapeutic landscape: emerging evidence about cardiac myosin inhibitors
31 August 2025
thumbnail
Congress Presentation
Hybrid telerehabilitation in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction and preserved left ventricular ejection fraction-the randomised clinical trial
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources